

14 September 2020

## Notice of Exercise of Options

**Minnesota, United States and Melbourne, Australia – 14 September 2020** – Osprey Medical Inc. (ASX:OSP) (**Osprey or the Company**) confirms that in accordance with the prospectus (**Prospectus**) issued for the 3 to 1 partially underwritten pro-rata renounceable entitlement offer announced by Osprey on 3 April 2020 (**Entitlement Offer**), the second exercise date for the unlisted options issued under the Entitlement Offer (**New Options**) is 14 October 2020.

Optionholders who wish to exercise all or part of their New Options must ensure that Osprey receives a Notice of Exercise of Options form together with the payment of the relevant exercise monies on or before **5pm** on **14 October 2020** (Melbourne time).

To assist optionholders a “*Notice of Exercise of Options*” form is attached to this announcement and the form will also be available on Osprey’s website.

Osprey also confirms that in accordance with the terms of the New Options detailed in the Prospectus:

- each New Option on exercise will entitle its holder to subscribe for one CHESSE Depository Interest (**CDI**);
- the exercise price per New Option is \$0.014 or 1.4 cents;
- the last exercise date for the New Options is 15 February 2021 (the date of their expiry);
- Pages 47 - 50 of the Prospectus set out the full terms and conditions of the New Options.

Osprey understands that a number of optionholders missed the previous exercise date of 15 June 2020, therefore Osprey encourages optionholders who wish to exercise all or part of their New Options in October to submit their Notice of Exercise of Options form together with the payment of the relevant exercise monies prior to the 14 October 2020 exercise date.

Osprey will also update the market in early October to remind those optionholders intending to exercise their New Options of the impending exercise date.

**This announcement has been approved by the President & Chief Executive Officer, Mike McCormick**

### Contact details:

#### Investor relations

Leijie Li  
Vesparum Capital  
T: (61) 3 8582 4800  
[ospreymed@vesparum.com](mailto:ospreymed@vesparum.com)

#### Company

Doug Schoenberg  
Vice President of Marketing  
T: (952) 955 8230  
[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)

### About Osprey Medical (ASX: OSP)

Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient’s risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (AKI). The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize

dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

### **Foreign Ownership Restriction**

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.